Oximes

Chemical Warfare Agents: Toxicology and Treatment, Second Edition

Volumn , Issue , 2007, Pages 305-329

  Eyer, Peter A ^a   Worek, Franz ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

2 pyridine aldoxime methiodide (2 PAM); Oxime history development; oximes against nerve agents in animals in vivo; Pyridinium oxime pharmacokinetics; Site directed mutagenesis and computational modelling

Indexed keywords

EID: 84890132026     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470060032.ch15     Document Type: Chapter

References (167)

1. Anderson DR, Harris LW, Woodard CL et al. (1992). The effect of pyridostigmine pretreatment on oxime efficacy against intoxication by soman or VX in rats. Drug Chem Toxicol, 15, 285-294.
2. Ashani Y and Pistinner S (2004). Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci, 77, 358-367.
3. Ashani Y, Bhattacharjee AK, Leader H et al. (2003). Inhibition of cholinesterases with cationic phosphonyl oximes highlights distinctive properties of the charged pyridine groups of quaternary oxime reactivators. Biochem Pharmacol, 66, 191-202.
4. AshaniY, Radic Z, Tsigelny I et al. (1995). Amino acid residues controlling reactivation of organophosphonyl conjugates of acetylcholinesterase by mono-and bisquaternary oximes. J Biol Chem, 270, 6370-6380.
5. Bajgar J, Patocka J, Jakl A et al. (1975). Antidotal therapy and changes of acetylcholinesterase activity following isopropyl methylphosphonofluoridate intoxication in mice. Acta Biol Med Germ, 34, 1049-1055.
6. Barkman R, Edgren B and Sundwall A (1963). Selfadministration of pralidoxime in nerve gas poisoning with a note on the stability of the drug. J Pharm Pharmacol, 15, 671-677.
7. Becker G, KawanAand Szinicz L (1997). Direct reaction of oximes with sarin, soman, or tabun in vitro. Arch Toxicol, 71, 714-718.
8. Bentur Y, Nutenko I, Tsipiniuk A et al. (1993). Pharmacokinetics of obidoxime in organophosphate poisoning associated with renal failure. Clin Toxicol, 31, 315-322.
9. Berry WK (1971). Some species differences in the rates of reaction of diaphragm particulate acetylcholinesterase with tetraethyl pyrophosphate and pralidoxime. Biochem Pharmacol, 20, 1333-1334.
10. Bismuth C, Inns RH and Marrs TC (1992). Efficacy, toxicity and clinical use of oximes in anticholinesterase poisoning. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 555-577. Oxford, UK: Butterworth-Heinemann.
11. Black ML(1955). The ionization constants of the pyridinium monocarboxylic acids: a reinterpretataion. J Phys Chem, 59, 670-671.
12. Boelcke G, Creutzfeldt W, Erdmann WD et al. (1970). Untersuchungen zur Frage der Lebertoxizität von Obidoxim (Toxogoninr® ) am Menschen. Dtsch med Wschr, 95, 1175-1178.
13. Boskovic B, Maksimovic M and Minic D(1968). Ageing and reactivation of acetylcholinesterase inhibited with soman and its thiocholine-like analogue. Biochem Pharmacol, 17, 1738-1741.
14. Brodin A and Wellenstam K (1996). Pharmaceutical and technical requirements, design, solutions and documentation of performance for binary autoinjectors. CBMTS 2. Spiez, Switzerland: NCLaboratory Spiez.
15. Busker RW, Zijlstra JJ, van der Wiel HJ et al. (1991). Organophosphate poisoning: a method to test therapeutic effects of oximes other than acetylcholinesterase reactivation in the rat. Toxicology, 69, 331-344.
16. Calesnick B, Christensen JA and Richter M (1967). Human toxicity of various oximes. 2-Pyridine aldoxime methyl chloride, its methane sulfonate salt and 1,1'-trimethylenebis-(4-formylpyridinium chloride). Arch Environ Health, 15, 599-608.
17. Chilcott RP, Dalton CH, Hill I et al. (2003). Clinical manifestations of VX poisoning following percutaneous exposure in the domestic white pig. Human Exp Toxicol, 22, 255-261.
18. Childs AF, Davies DR, Green AL et al. (1955). The reactivation by oximes and hydroxamic acids of cholinesterase inhibited by organo-phosphorus compounds. Brit J Pharmacol, 10, 462-465.
19. Christenson I (1968a). Hydrolysis of bis(4-hydroxyiminomethyl-1-pyridiniomethyl)ether dichloride (Toxogoninr®). I. Decomposition products. Acta Pharm Suec, 5, 23-36.
20. Christenson I (1968b). Hydrolysis of bis(4-hydroxyiminomethyl-1-pyridiniomethyl)ether dichloride (Toxogoninr® ). II. Kinetics and equilibrium in acidic solution. Acta Pharm Suec, 5, 249-262.
21. Christenson I (1972). Hydrolysis of obidoxime chloride (Toxogoninr® ). III. Kinetics in neutral and alkaline solution. Acta Pharm Suec, 9, 309-322.
22. Clement JG (1992). Central activity of acetylcholinesterase oxime reactivators. Toxicol Appl Pharmacol, 112, 104-109.
23. Clement JG and Erhardt N (1994). In vitro oximeinduced reactivation of various molecular forms of soman-inhibited acetylcholinesterase in striated muscle from rat, monkey and human. Arch Toxicol, 68, 648-655.
24. Clement JG, Pierce CH and Houle J-M (1992a). Ascending dose tolerance study of the oxime, HI-6, in man. In: Proceedings of the 4th International Symposium on Protection against Chemical Warfare Agents, 287-296, FAO Report A40067-4.6, 4.7. Stockholm, Sweden.
25. Clement JG, Hansen AS and Boulet CA (1992b). Efficacy of HLö-7 and pyrimidoxime as antidotes of nerve agent poisoning in mice. Arch Toxicol, 66, 216-219.
26. Clement JG, Madill HD, Bailey D et al. (1994). Clinical study of a new therapy for nerve agent poisoning: Ascending dose tolerance study of HI 6 and atropine. Suffield Report, pp. 1-32. Suffield. AB, Canada: Defence Research Establishment.
27. Clement JG, Bailey DG, Madill HD et al. (1995). The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine. Biopharm Drug Disposit, 16, 415-425.
28. Craig FN, Cummings EG and Sim VM (1977). Environmental temperature and the percutaneous absorption of a cholinesterase inhibitor, VX. J Invest Dermatol, 68, 357-361.
29. Creasey HN and Green AC (1959). 2-Hydroxyiminomethyl-N-methyl-pyridiniummethansulfonate (P2S), an antidote to organophosphorus poisoning. Its preparation, estimation, and stability. J Pharm Pharmacol, 11, 485-490.
30. Dawson RM (1994). Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol, 14, 317-331.
31. De Jong LPA and Ceulen DI (1978). Anticholinesterase activity and rate of decomposition of some phosphylated oximes. Biochem Pharmacol, 27, 857-863.
32. De Jong LPA and Wolring GZ (1984). Stereospecific reactivation by some Hagedorn-oximes of acetylcholinesterases from various species including man, inhibited by soman. Biochem Pharmacol, 33, 1119-1125.
33. De Jong LPA, Verhagen MAA, Langenberg JP et al. (1989). The bispyridinium-dioxime HLö 7. A potent reactivator for acetylcholinesterase inhibited by the stereoisomers of tabun and soman. Biochem Pharmacol, 38, 633-640.
34. De Jong LPA, Langenberg JP, van Dijk C et al. (1996). Development of a physiologically based model for the toxicokinetics of C(+-)P(+-)-soman in the atropinized guinea pig. Proc Med Def Biosci Rev, pp. 71-80.
35. Dirnhuber P, French MC, GreenDMet al. (1979). The protection of primates against soman poisoning by pretreatment with pyridostigmine. J Pharm Pharmacol, 31, 295-299.
36. Duncan RC and Griffith J (1992). Screening of agricultural workers for exposure to anticholinesterases. In: Clinical and Experimental Toxicology of Organophosphates and Carbamates (B Ballantyne and TC Marrs, eds), pp. 421-429. Oxford, UK: Butterworth-Heinemann.
37. Ellenhorn MJ and Barceloux DG (1988). Medical Toxicology: Diagnosis and Treatment of Human Poisoning. New York, NY, USA: Elsevier.
38. Ellin RI (1982). Stability of concentrated aqueous solutions of pralidoxime chloride. J Pharmaceut Sci, 71, 1057-1059.
39. Ellin RI, Carlese JS and Kondritzer AA(1962). Stability of pyridine-2-aldoxime methiodide II. Kinetics of deterioration in dilute aqueous solutions. J Pharmaceut Sci, 51, 141-146.
40. Ellin RI, Groff WA and Sidell FR (1974). Passage of pyridinium oximes into human red cells. Biochem Pharmacol, 23, 2663-2670.
41. Enander I, Sundwall A and Sörbo B (1962). Metabolic studies on N-methylpyridinium-2-aldoxime-III. Experiments with the 14C-labelled compound. Biochem Pharmacol, 11, 377-382.
42. Erdmann WD and von Clarmann M (1963). Ein neuer Esterase-Reaktivator für die Behandlung von Vergiftungen mit Alkylphosphaten. Dtsch med Wschr, 88, 2201-2206.
43. Erdmann WD, Bosse I and Franke P (1965). Zur Resorption und Ausscheidung vonToxogonin nach intramuskul ärer Injektion am Menschen. Dtsch med Wschr, 90, 1436-1438.
44. Eyer P (1996). Optimal oxime dosage regimen, a pharmacokinetic approach. In: Role of Oximes in the Treatment of Anticholinesterase Agent Poisoning (L Szinicz, P Eyer and R Klimmek, eds), pp. 33-51. Heidelberg, Germany: Spektrum, Akademischer Verlag.
45. Eyer P (2003). The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev, 22, 165-190.
46. Eyer P, Hell W, Kawan A et al. (1986). Studies on the decomposition of the oxime HI 6 in aqueous solution. Arch Toxicol, 59, 266-271.
47. Eyer P, Kawan A and Ladstetter B (1987). Formation of cyanide after i.v. administration of the oxime HI 6 to dogs. Arch Toxicol, 61, 63-69.
48. Eyer P, Hagedorn I and Ladstetter B (1988). Study on the stability of the oxime HI 6 in aqueous solution. Arch Toxicol, 62, 224-226.
49. Eyer P, Ladstetter B, Schäfer W et al. (1989). Studies on the stability and decomposition of the Hagedornoxime HLö 7 in aqueous solution. Arch Toxicol, 63, 59-67.
50. Eyer P, Hagedorn I, Klimmek R et al. (1992). HLö 7 dimethanesulfonate, a potent bispyridiniumdioxime against anticholinesterases. Arch Toxicol, 66, 603-621.
51. Fleisher JH and Harris LW (1965). Dealkylation as a mechanism for aging of cholinesterase after poisoning with pinacolyl methylphosphonofluoridate. Biochem Pharmacol, 14, 641-650.
52. Fyhr P, Brodin A, Ernerot L et al. (1986). Degradation pathway of pralidoxime chloride in concentrated acidic solution. J Pharm Sci, 75, 608-611.
53. Garrigue H, Maurizis JC, Nicolas C et al. (1990). Disposition and metabolism of two acetylcholinesterase reactivators, pyrimidoxime and HI6, in rats submitted to organophosphate poisoning. Xenobiotica, 20, 699-709.
54. Garrigue H, Maurizis JC, Madelmont JC et al. (1991). Disposition and metabolism of acetylcholinesterase reactivators 2PAM-I, TMB4 and R665 in rats submitted to organophosphate poisoning. Xenobiotica, 21, 583-595.
55. Gordon JJ, Leadbeater L and Maidment MP (1978). The protection of animals against organophosphate poisoning by pretreatment with a carbamate. Toxicol Appl Pharmacol, 43, 207-216.
56. Grange-Messenet, Bouchaud C, Jamme M et al. (1999). Seizure-related opening of the blood-brain barrier produced by the anticholinesterase compound, soman: new ultrastructural observations. Cell Mol Biol, 45, 1-14.
57. Green AL and Saville B(1956). The reaction of oximes with isopropyl methylphosphonofluoridate (sarin). J Chem Soc, 3, 3887-3892.
58. Hackley Jr BE, Steinberg GM and Lamb JC (1959). Formation of potent inhibitors of AChE by reaction of pyridinaldoximes with isopropyl methylphosphonofluoridate (GB). Arch Biochem Biophys, 80, 211-214.
59. Hagedorn I, Stark I and Lorenz HP (1972). Reaktivierung phosphorylierter Acetylcholin-Esterase-Abhängigkeit von der Aktivator-Acidität. Angew Chem, 84, 354-356.
60. HamiltonMGand Lundy PM (1989). HI-6 Therapy of soman and tabun poisoning in primates and rodents. Arch Toxicol, 63, 144-149.
61. Hanke DW and Overton MA (1991). Phosphylation kinetic constants and oxime-induced reactivation in acetylcholinesterase from fetal bovine serum, bovine caudate nucleus, and electric eel. J Toxicol Environ Health, 34, 141-156.
62. Harris LW, Fleisher JH, Clark J et al. (1966). Dealkylation and loss of capacity for reactivation of cholinesterase inhibited by sarin. Science, 154, 404-407.
63. Harris LW, Anderson DR, Lennox WJ et al. (1990). Evaluation of several oximes as reactivators of unaged soman-inhibited whole blood acetylcholinesterase in rabbits. Biochem Pharmacol, 40, 2677-2682.
64. Hartwich WJ (2004). Untersuchungen zur schnellen Freigabe von HI6 Dichlorid und HI 6 Dimethansulfonat aus verschiedenen Autoinjektorsystemen, pp. 1-127. MD Thesis. Munich, Germany: Medical Faculty, Ludwig Maximilians University.
65. Hobbiger F (1963). Reactivation of phosphorylated acetylcholinesterase. In: Cholinesterases and Anticholinesterase Agents, Vol. XV (GB Koelle, ed.), pp. 921-988. Berlin, Germany: Springer-Verlag.
66. Hobbiger F and Sadler PW (1959). Protection against lethal organophosphate poisoning by quaternary pyridine aldoximes. Brit J Pharmacol, 14, 192-201.
67. Hobbiger F, O'Sullivan DG and Sadler PW (1958). New potent reactivators of acetycholinesterase inhibited by tetraethyl pyrophosphate. Nature, 182, 1498-1499.
68. Holcombe DG (1986). Stability of pralidoxime mesylate injections. Anal Proc, 23, 320-321.
69. Inns RH and Leadbeater L (1983). The efficacy of bispyridinium derivatives in the treatment of organophosphate poisoning in the guinea pig. J Pharm Pharmacol, 35, 427-433.
70. Jager BV and Stagg GN (1958). Toxicity of diacetylmonoxime and of pyridine-2-aldoxime methiodide in man 15-30 mg/kg 2-PAM: no effects on EEG in a healthy man. Bull Johns Hopkins Hosp, 102, 203-211.
71. Josselson J and Sidell FR (1978). Effect of intravenous thiamine on pralidoxime kinetics. Clin Pharmacol Ther, 24, 95-100.
72. Jovanovic D (1989). Pharmacokinetics of pralidoxime chloride.Acomparative study in healthy volunteers and in organophosphorus poisoning. Arch Toxicol, 63, 416-418.
73. Jovanovic D, Randjelovic S and Joksovic D (1990). A case of unusual suicidal poisoning by the organophosphorus insecticide dimethoate. Human Exp Toxicol, 9, 49-51.
74. Kassa J and Cabal J (1999). A comparison of the efficacy of a new asymmetric bispyridinium oxime BI-6 with presently used oximes and H oximes against sarin by in vitro and in vivo methods. Human Exp Toxicol, 18, 560-565.
75. Kepner LA and Wolthuis OL (1978). A comparison of the oximes HS-6 and HI-6 in the therapy of soman intoxication in rodents. Eur J Pharmacol, 48, 377-382.
76. Kiderlen D, Eyer P and Worek F (2005). Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase PON1. Biochem Pharmacol, 69, 1853-1867.
77. Klimmek R and Eyer P (1986). Pharmacokinetics and pharmacodynamics of the oxime HI 6 in dogs. Arch Toxicol, 59, 272-278.
78. Kondritzer A, Ellin RT and Edberg LJ (1961). Investigation of methyl pyridinium-2-aldoxime salts. J Pharm Sci, 50, 109-112.
79. Koplovitz I and Stewart JR (1992). Efficacy of oxime plus atropine treatment against soman poisoning in the atropinesterase-free rabbit. Drug Chem Toxicol, 15, 117-26.
80. Korte WD and Shih ML (1993). Degradation of three related bis(pyridinium)aldoximes in aqueous solutions at high concentrations: Examples of unexpectedly rapid amide group hydrolysis. J Pharm Sci, 82, 782-786.
81. Kovarik Z, Radic Z, Berman HA et al. (2004). Mutant cholinesterases possessing enhanced capacity for reactivation of their phosphonylated conjugates. Biochemistry, 43, 3222-3229.
82. Kozer E, Mordel A, Haim SB et al. (2005). Pediatric poisoning from trimedoxime (TMB4) and atropine automatic injectors. J Pediatr, 146, 41-44.
83. Krummer S, Thiermann H, Worek F et al. (2002). Equipotent cholinesterase reactivation in vitro by the nerve agent antidotes HI 6 dichloride and HI 6 dimethanesulfonate. Arch Toxicol, 76, 589-595.
84. Kusic R, Boskovic B,Vojvodic V et al. (1985). HI-6 in man: blood levels, urinary excretion, and tolerance after intramuscular administration of the oxime to healthy volunteers. Fund Appl Toxicol, 5, S89-S97.
85. Kusic R, Jovanovic D, Randjelovic S et al. (1991). HI-6 in man: Efficacy of the oxime in poisoning by organophosphorus insecticides. Human Exp Toxicol, 10, 113-118.
86. Ladstetter B (1990). Stabilität und metabolisches Schicksal neuer Antidote gegen Organophosphate. PhD Thesis. Munchen, Germany: Universität München.
87. Lamb JC, Steinberg GM, Solomon S et al. (1965). Reaction of 4-formyl-1-methylpyridinium iodide oxime with isopropyl methylphosphonofluoridate. Biochemistry, 4, 2475-2484.
88. Langenberg JP, van Dijk C, Sweeney RE et al. (1997). Development of a physiologically based model for the toxicokinetics of C(+-)P(+-)-soman in the atropinized guinea pig. ArchToxicol, 71, 320-331.
89. Leadbeater L, Inns RH and Rylands JM (1985). Treatment of poisoning by soman. Fund Appl Toxicol, 5, S225-S231.
90. Leader H,Vincze A, Manisterski B et al. (1999). Characterization of O,O-diethylphosphoryl oximes as inhibitors of cholinesterases and substrates of phosphotriesterases. Biochem Pharmacol, 58, 503-515.
91. Ligtenstein DA and Kossen SP (1983). Kinetic profile in blood and brain of the cholinesterase reactivating oxime HI-6 after intravenous administration to the rat. Toxicol Appl Pharmacol, 71, 177-183.
92. Ligtenstein DA, Wils ERJ, Kossen SP et al. (1987). Identification of two metabolites of the cholinesterase reactivator HI-6 isolated from rat urine. J Pharm Pharmacol, 39, 17-23.
93. Lin AJ and Klayman DL (1986). Stability studies of bis(pyridiniumaldoxime) reactivators of organophosphate inhibited acetylcholinesterase. J Pharm Sci, 75, 797-799.
94. Lockridge O and Masson P (2000). Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk. NeuroToxicology, 21, 113-126.
95. Löffler M (1986). Quartäre Salze von Pyridin-2,4-Dialdoxim als Gegenmittel für Organophosphat-Vergiftungen PhD Thesis. Freiburg in Bresgau, Germany: Albert Ludwigs Universität.
96. Lotti M and Becker CE (1982). Treatment of acute organophosphate poisoning: Evidence of a direct effect on central nervous system by 2-PAM (pyridine-2-aldoxime methyl chloride). Clin Toxicol, 19, 121-127.
97. Luo C, AshaniYand Doctor BP (1998a). Acceleration of oxime-induced reactivation of organophosphateinhibited fetal bovine serum acetylcholinesterase by monoquaternary and bisquaternary ligands. Mol Pharmacol, 53, 718-726.
98. Luo C, AshaniY, Saxena A et al. (1998b). Acceleration of oxime-induced reactivation of organophosphateinhibited acetylcholinesterase by quaternary ligands. In: Structure and Function of Cholinesterases and Related Proteins (BP Doctor, P Taylor, DM Quinn et al.), pp. 215-221. New York, NY, USA: Plenum Press.
99. Luo C, Saxena A, Smith M et al. (1999). Phosphoryl oxime inhibition of acetylcholinesterase during oxime reactivation is prevented by edrophonium. Biochemistry, 38, 9937-9947.
100. Lüttringhaus A and Hagedorn I (1964). Quartäre Hydroxyiminomethyl-pyridiniumsalze. Das Dichlorid des Bis-[4-hydroxyiminomethyl-pyridinium-(1)-methyl]-äthers ("LüH6"), ein neuer Reaktivator der durch organische Phosphorsäureester gehemmten Acetylcholin-Esterase. Arzneim Forsch, 14, 1-5.
101. Marrs TC (1991). Toxicology of oximes used in treatment of organophosphate poisoning. Adverse Drug React Toxicol Rev, 10, 61-73.
102. Mast U (1997). Reaktivierung der Erythrozyten-Acetylcholinesterase durch Oxime. Ermittlung enzymkinetischer Konstanten und ihre Bedeutung für die Therapie einer Organophosphat-Vergiftung. MD Thesis. Ludwig-Maximilians-Universität München, Germany.
103. Maurizis JC, Ollier M, Nicolas C et al. (1992). In vitro binding of oxime acetylcholinesterase reactivators to proteoglycans synthesized by cultured chondrocytes and fibroblasts. Biochem Pharmacol, 44, 1927-1933.
104. Maxwell DM and Brecht KM (1991). The role of carboxylesterase in species variation of oxime protection against soman. Neurosci Biobehav Rev, 15, 135-139.
105. Maxwell DM, Brecht KM and Koplovitz I (1997). Characterization and treatment of the toxicity of O-isobutyl S-[2-(diethylamino) ethyl]methylphosphonothioate, a structural isomer of VX, in guinea pigs. J Am Coll Toxicol, 15 (Supplement 2), S78-S88.
106. Mdachi RE, Marshall WD, Ecobichon DJ et al. (1990). Abiotic transformations and decomposition kinetics of 4-carbamoyl-2'-[hydroxyimino)methyl]-1,1'-(oxydimethylene)-bis(pyridiniu m chloride) in aqueous phosphate buffers. Chem Res Toxicol, 3, 413-422.
107. Medicis JJ, Stork CM, Howland MA et al. (1996)Pharmacokinetics following a loading plus a continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers. Clin Toxicol, 34, 289-295.
108. Melchers BPC, Van der Laaken AL and Van Helden HPM (1991). On the mechanism whereby HI-6 improves neuromuscular function after oximeresistant acetylcholinesterase inhibition and subsequent impairment of neuromuscular transmission. Eur J Pharmacol, 200, 331-337.
109. Nenner M (1974). Phosphonylierte Aldoxime. Hemmwirkung auf Acetylcholinesterase und hydrolytischer Abbau. Biochem Pharmacol, 23, 1255-1262.
110. Oldiges H and Schoene K (1970). Pyridinium-und Imidazoliumsalze als Antidote gegenüber Somanund Paraoxonvergiftungen bei Mäusen. Arch Toxicol, 26, 293-305.
111. Portmann R, Niederhauser A, Hofmann W et al. (1991). 32. Synthesis of 4-(([(isopropyloxy) methylphosphoryloxy]imino)methyl)-1-methylpyridinium iodide and its characterisation. Helv Chim Acta, 74, 331-335.
112. Poziomek EJ, Hackley Jr BE and Steinberg GM (1958). Pyridinium aldoximes. J Org Chem, 23, 714-717.
113. Primozic I, Odzak R, Tomic S et al. (2004). Pyridinium, imidazolium and quinuclidinium oximes: synthesis, interaction with native and phosphylated cholinesterases, and antidotes against organophosphorus compounds. JMedChem Def, 2, 1-30.
114. Prinz HJ (1967). Therapie akuter Alkylphosphat-Vergiftungen. Dtsch Ärztebl, 36, 1845-1849.
115. Radic Z and Taylor P (1999). The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact, 119, 111-117.
116. Rubnov S, Amisar S, Levy D et al. (1999a). Stability of trimedoxime in concentrated acidic injectable solutions. Mil Med, 164, 55-58.
117. Rubnov S, Shats I, SchulzVet al. (1999b). Autocatalytic degradation and stability of obidoxime. J Pharm Pharmacol, 51, 9-14.
118. Schlager JW, Dolzine TW, Stewart JR et al. (1991). Operational evaluation of three commercial configurations of atropine/HI-6 wet/dry autoinjectors. Pharm Res, 8, 1191-1194.
119. Schoene K (1973). Phosphonyloxime aus Soman; Bildung und Reaktion mit Acetylcholinesterase in vitro. Biochem Pharmacol, 22, 2997-3003.
120. Schroeder AC, DiGiovanni JH, von Bredow J et al. (1989). Pralidoxime chloride stability-indicating assay and analysis of solution samples stored at room temperature for ten years. J Pharm Sci, 78, 132-136.
121. SchulzV, Gross R, Pasch T et al. (1982). Cyanide toxicity of sodium nitroprusside in therapeutic use with and without sodium thiosulfate. Klin WochenSchr, 60, 1393-1400.
122. Scott RJ (1986). Repeated asystole following PAM in organophosphate self-poisoning. Anaesth Intens Care, 14, 458-60.
123. Shafferman A, Ordentlich A, Barak D et al. (1996). Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Biochem J, 318, 833-840.
124. Sidell FR (1974). Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. ClinToxicol, 7, 1-17.
125. Sidell FR (1992). Clinical considerations in nerve agent intoxication. In: Chemical Warfare Agents (SM Somani, ed.), pp. 155-194. San Diego, CA, USA: Academic Press.
126. Sidell F (1997). Nerve agents. In: Medical Aspects of Chemical and Biological Warfare (F Sidell, ET Takafuji and DR Franz, eds), pp. 130-179. Washington, DC, USA:Walter Reed Army Medical Center.
127. Sidell FR and Groff WA (1970). Toxogonin: Blood levels and side effects after intramuscular administration in man. J Pharm Sci, 59, 793-797.
128. Sidell FR and Groff WA (1971). Intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime methochloride to man. J Pharm Sci, 60, 1224-1228.
129. Sidell FR and GroffWA (1974). The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol, 27, 241-252.
130. Sidell FR, Groff WA and Kaminskis A (1972). Toxogonin and pralidoxime: Kinetic comparison after intravenous administration to man. J Pharm Sci, 61, 1765-1769.
131. Simon GA, Tirosh MS and Edery H (1976). Administration of obidoxime tablets to man. Plasma levels and side reactions. Arch Toxicol, 36, 83-88.
132. Smith TE and Usdin E (1966). Formation of nonreactivatible isopropylmethylphosphonofluoridateinhibited acetylcholinesterase. Biochemistry, 5, 2914-2918.
133. Spöhrer U (1994). HPLC-analytische Untersuchungen zur Pharmakokinetik von Pyridiniumaldoximen. PhD Thesis. Ludwig-Maximilians-Universität München, Germany.
134. Spöhrer U and Eyer P (1995). Separation of geometrical syn/anti isomers of obidoxime by ion-pair highperformance liquid chromatography. J Chromatgr A, 693, 55-61.
135. Spöhrer U, Thiermann H, Klimmek R et al. (1994). Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. Arch Toxicol, 68, 480-489.
136. Spruit HE, Langenberg JP, Trap HC et al. (2000). Intravenous and inhalation toxicokinetics of sarin stereoisomers in atropinized guinea pigs. Toxicol Appl Pharmacol, 169, 249-54.
137. Stark I (1968). Versuche zur Darstellung eines LüH6 (Toxogonin) überlegenen Acetylcholinesterase-Reaktivators. Freiburg in Bresgau, Germany: Albert Ludwigs Universität.
138. Stemler FW, Tezak-Reid TM, McCluskey MP et al. (1991). Pharmacokinetics and pharmacodynamics of oxime in unanesthetized pigs. Fund Appl Toxicol, 16, 548-558.
139. Su C-T, Wang P-H, Liu R-F et al. (1986). Kinetic studies and structure-activity relationships of bispyridinium oximes as reactivators of acetylcholinesterase inhibited by organophosphorus compounds. Fund Appl Toxicol, 6, 506-524.
140. Sundwall A(1960). Plasma concentration curves of Nmethylpyridinium-2-aldoxime methane sulphonate (P2S) after intravenous, intramuscular and oral administration in man. Biochem Pharmacol, 5, 225-230.
141. Sussman JL, Harel M, Frolow F et al. (1991). Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science, 253, 872-879.
142. Sweeney RE and Maxwell DM (1999). A theoretical model of the competition between hydrolase and carboxylesterase in protection against organophosphorus poisoning. Math Biosci, 160, 175-190.
143. Sweeney RE and Maxwell DM (2003). A theoretical expression for the protection associated with stoichiometric and catalytic scavengers in a single compartment model of organophosphorus poisoning. Math Biosci, 181, 133-143.
144. Talbot BG, Anderson DR, Harris LW et al. (1988). A comparison of in vivo and in vitro rates of ageing of soman-inhibited erythrocyte anticholinesterase in different animal species. Drug Chem Toxicol, 11, 289-305.
145. Tattersall JE, Smith AP, Waters K et al. (1998). Therapeutic action of HI-6 against soman poisoning in vitro: an interspecies comparison. Br J Pharmacol, 125, 7P.
146. Taylor P, Wong L, Radic Z et al. (1999). Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity. Chem-Biol Interact, 119-120, 3-15.
147. Thiermann H, Spöhrer U, Klimmek R et al. (1994). Operational evaluation of wet/dry autoinjectors containing atropine in solution and powdered HI 6 or HLö 7. Int J Pharm, 109, 35-43.
148. Thiermann H, Seidl S and Eyer P (1995a). Stand der Entwicklung neuer Autoinjektoren zur Behandlung der Nervenkampfstoff-Vergiftung. Wehrmed Mschr, 39, 189-192.
149. Thiermann H, Spöhrer U, Klimmek R et al. (1995b). Pharmacokinetics of atropine and its combination with HI 6 or HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors. Przeg Lek, 52, 208.
150. Thiermann H, Seidl S and Eyer P (1996). HI 6 dimethanesulfonate has better dissolution properties than HI 6 dichloride for application in dry/wet autoinjectors. Int J Pharm, 137, 167-176.
151. Utley D (1987). Analysis of formulations containing pralidoxime mesylate by liquid chromatography. J Chromatogr, 396, 237-250.
152. van der Schans MJ, Lander BJ, van der Wiel H et al. (2003). Toxicokinetics of the nerve agent (+/-)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol Appl Pharmacol, 191, 48-62.
153. van HeldenHPM,de Lange J, BuskerRWet al. (1991). Therapy of organophosphate poisoning in the rat by direct effects of oximes unrelated to ChE reactivation. Arch Toxicol, 65, 586-593.
154. van Helden HPM, Busker RW, Melchers BPC et al. (1996). Pharmacological effects of oximes: how relevant are they? Arch Toxicol, 70, 779-786.
155. Vojvodic V and Boskovic B (1976). A comparative study of pralidoxime, obidoxime and trimedoxime in healthy men volunteers and in rats. In: Medical Protection against Chemical-Warfare Agents (J Stares, ed.), pp. 65-73. SIPRI, Stockholm, Sweden: Almqvist & Wiksell.
156. von Gaisberg U and Dieterle K (1967). Organ-Parenchymschäden nach E-605-Vergiftung bzw. hochdosierter Toxogoninbehandlung. Dtsch Ärztebl, 64, 1791-1796.
157. Wiezorek WD, Kreisel W, Schnitzlein W et al. (1968). Eigenwirkungen von Trimedoxim und Pralidoxim am Menschen. Zeitschr Militärmed, 4, 223-226.
158. Willems JL, Langenberg JP, Verstraete AG et al. (1992). Plasma concentrations of pralidoximemethylsulphate in organophosphorus poisoned patients. Arch Toxicol, 66, 260-266.
159. Wilson IB and Ginsburg S (1955). A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase. Biochim Biophys Acta, 18, 168-170.
160. Wong L, Radic Z, Brüggemann RJM et al. (2000). Mechanism of oxime reactivation of acetylcholinesterase analyzed by chirality and mutagenesis. Biochemistry, 39, 5750-5757.
161. Woodard CL and Lukey BJ (1991). MMB-4 pharmacokinetics in rabbits after intravenous and intramuscular administration. Drug Metab Dispos, 19, 283-284.
162. Worek F, Eyer P and Szinicz L (1998). Inhibition, reactivation, and aging kinetics of cyclohexylmethylphosphonofluoridate-inhibited human cholinesterases. Arch Toxicol, 72, 580-587.
163. Worek F, Eyer P, Kiderlen D et al. (2000). Effect of human plasma on the reactivation of sarin-inhibited human erythrocyte acetylcholinesterase. Arch Toxicol, 74, 21-26.
164. Worek F, Reiter G, Eyer P et al. (2002). Reactivation kinetics of acetylcholinesterase from different species inhibited by highly toxic organophosphates. Arch Toxicol, 76, 523-529.
165. Worek F, Thiermann H, Szinicz L et al. (2004). Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem Pharmacol, 68, 2237-48.
166. Worek F, Szinicz L, Eyer P et al. (2005). Evaluation of oxime efficacy in nerve agent poisoning: development of a kinetic-based dynamic model. Toxicol Appl Pharmacol, 209, 193-202.
167. Xue SZ, Ding XJ and Ding Y (1985). Clinical observation and comparison of the effectiveness of several oxime cholinesterase reactivators. Scand J Work Environ Health, 11, 46-48.